Based on the BPET prototype developed at ETH Zurich, Positrigo strives for the certification of it’s NeuroLF imaging system as a medical device under CE and FDA regulations and enter the market by 2022/23.
Our technology was developed at ETH Zurich with support from University of Zurich and University Hospital of Zurich.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements No. 855292 and No. 953844.